Standard TB antibiotics are directed against the pathogen, but various host directed immune therapies, including reduction of PGE2 production by COX- inhibitors (COX-i) has potential to become part of a treatment strategy for resistant or clinically complicated TB cases or as part of a TB vaccination scheme [18–20]. Here, MT-CO1 is linked to tuberculosis.